Similarly, in their multicenter observational study, Cortellini et al. also reported that a lower skeletal muscle index was significantly associated with shorter OS time in advanced NSCLC patients treated with anti PD‐1/PD‐L1 antibody therapy.15 The gene discussed is CD274; the disease is non-small cell lung carcinoma.